Directorate Change

GW Appoints Cabot Brown as a Non-Executive Director

Porton Down, UK; February 19 2013:GW Pharmaceuticals plc (AIM:GWP) today announces the appointment of Cabot Brown as a non-executive director with immediate effect. Mr Brown will sit on the Nominations Committee, Audit Committee, as well as the Remuneration Committee.

Cabot Brown, aged 51, has more than 30 years of experience in the financial industry specialising in the health care sector. Mr Brown is the founder of Carabiner LLC, an advisory and private equity firm based in San Francisco and London that specializes in health care and education. Previously, Mr Brown served as a Managing Director at GCA Savvian, an international financial advisory firm, where he directed the firm's efforts in the health care industry. Before joining GCA Savvian in 2011, Mr Brown worked for ten years at Seven Hills Group, an investment banking group based in San Francisco, of which he was a co-founder and where he directed the firm's health care activities. Prior to Seven Hills, he was Managing Director of Brown, McMillan & Co., a U.S. investment firm he co-founded that sponsored buy-outs and venture capital investments.

From 1987 until 1995, Mr Brown worked at Volpe, Welty & Company, a U.S. investment bank, where he co-founded and ran the health care practice and served as a member of its Executive Committee. Mr Brown started his finance career in New York, working in the investment banking departments of The First Boston Corporation and Lehman Brothers. Mr Brown holds an M.B.A. from Harvard Business School with high distinction as a George F. Baker Scholar and an A.B. cum laude in Government from Harvard College.

Dr Geoffrey Guy, Chairman, said, "We are very pleased to welcome Cabot to the Board. Having spent 25 years in investment banking in the United States providing strategic financial advice to companies in the health care sector, Cabot brings a wealth of valuable expertise to our Board. In particular, we see the United States as a country of increasing importance to the future of our business as we move towards completion of the pivotal Phase III cancer pain trials programme in that country for our lead product, Sativex®. We look forward to benefiting from Cabot's experience and advice in the years ahead."

The following disclosures are made in accordance with AIM rule 17 and Schedule 2 paragraph (g) of the AIM rules:

Cabot Brown has been a Director/Partner of the following companies in the previous five years:

GCA Savvian Advisors, Managing Director

Seven Hills Group LLC, Managing Director, Board of Advisors

Brown, McMillian & Co., Managing Director

Until 1979, Cabot Brown was called Stephen Cabot Brown, Jr.

Enquiries:

Notes to Editors:

About GW

GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com